Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omarigliptin in Young Adults with Type 2 Diabetes
NCT01814748Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of omarigliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started May 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01814748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814748.